Search | Clinical Trials Finder

Conditions: Short Bowel Syndrome
Interventions: Glepaglutide, Placebo; Drug · Other
Lead sponsor: Zealand Pharma; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 6
States / cities: Chicago, Illinois • St Louis, Missouri • Omaha, Nebraska + 3 more

Conditions: Systemic Lupus Erythematosus
Interventions: Efavaleukin Alfa, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 6
States / cities: Anniston, Alabama • Beverly Hills, California • Aventura, Florida + 3 more

Conditions: Myasthenia Gravis
Interventions: Nipocalimab, Placebo, Nipocalimab SC-LIV; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 24
States / cities: Paradise Valley, Arizona • Scottsdale, Arizona • Los Angeles, California + 21 more

Conditions: Moderate-to-Severe Atopic Dermatitis
Interventions: Rezpegaldesleukin, Placebo; Drug
Lead sponsor: Nektar Therapeutics; Industry
Eligibility: 12 Years and older
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 19
States / cities: Phoenix, Arizona • North Little Rock, Arkansas • Fountain Valley, California + 15 more

Conditions: NASH With Fibrosis, MASH With Fibrosis
Interventions: Efruxifermin, Placebo; Drug
Lead sponsor: Akero Therapeutics, Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 200
States / cities: Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 160 more

Conditions: Early Rheumatoid Arthritis
Interventions: Adalimumab, Methotrexate, Adalimumab placebo, Methotrexate placebo; Biological · Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years and older
Enrollment: 799 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2012
U.S. locations: 31
States / cities: Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 24 more

Conditions: Type 2 Diabetes
Interventions: E1 and G1; Drug
Lead sponsor: OPKO Health, Inc.; Industry
Eligibility: 30 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 3
States / cities: Chula Vista, California • Clearwater, Florida • San Antonio, Texas

Conditions: Obesity
Interventions: survodutide, Placebo; Combination Product
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 5,531 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 153
States / cities: Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 135 more

Conditions: Migraine
Interventions: Lu AG09222, Placebo; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Glendale, California

Conditions: Pancreatic Cancer
Interventions: Pasireotide (SOM230), placebo; Drug · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 439 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Severe Eosinophilic Chronic Sinusitis Without Nasal Polyposis
Interventions: Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT], Placebo; Drug · Other
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Migraine
Interventions: Fremanezumab, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 1,890 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 90
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 75 more

Conditions: Hidradenitis Suppurativa (HS)
Interventions: Tibulizumab Dose A, Tibulizumab Dose B, Placebo; Biological · Other
Lead sponsor: Zura Bio Inc; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 34
States / cities: Phoenix, Arizona • Irvine, California • Los Angeles, California + 30 more

Conditions: Migraine
Interventions: MEDI0618, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 488 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 16
States / cities: Birmingham, Alabama • Huntsville, Alabama • La Jolla, California + 13 more

Conditions: Autoimmune Diseases of the Nervous System, Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Disease Progression, Brain Atrophy
Interventions: Tcelna, Placebo; Biological
Lead sponsor: Opexa Therapeutics, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 33
States / cities: Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 28 more

Conditions: Immune Thrombocytopenic Purpura (ITP)
Interventions: Mezagitamab, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 25
States / cities: Hot Springs, Arkansas • Los Angeles, California • San Diego, California + 21 more

Conditions: Primary Membranous Nephropathy
Interventions: ALXN1920, Placebo; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 5
States / cities: Loma Linda, California • San Diego, California • Minneapolis, Minnesota + 2 more

Conditions: Migraine Headache
Interventions: Erenumab 70 mg, Erenumab 140 mg, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 620 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 32
States / cities: Cerritos, California • Colton, California • Los Angeles, California + 28 more

Conditions: Familial Mediterranean Fever
Interventions: Rilonacept, Placebo; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 4 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 5
States / cities: Los Angeles, California • Madera, California • Bethesda, Maryland + 2 more

Conditions: Multiple Myeloma
Interventions: Ramantamig, Tocilizumab, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Beverly Hills, California

Conditions: Alopecia Areata
Interventions: LAD603, Placebo; Drug · Other
Lead sponsor: Almirall, S.A.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection
Interventions: Evolocumab, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 467 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 20
States / cities: Los Angeles, California • Hartford, Connecticut • Washington D.C., District of Columbia + 15 more

Conditions: Asthma
Interventions: Dupilumab, Placebo, Oral corticosteroid therapy (prednisone/prednisolone), Inhaled corticosteroid (ICS) therapy, Albuterol/Salbutamol, Levalbuterol/Levosalbutamol; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 8
States / cities: Los Angeles, California • Rolling Hills Estates, California • St Louis, Missouri + 4 more

Conditions: Healthy Volunteers
Interventions: BIIB107, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 3
States / cities: Anaheim, California • Miami, Florida • Overland Park, Kansas

Search by objective public record fields.

Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efavaleukin Alfa in Participants With Systemic Lupus Erythematosus

A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis

A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis

A Study in Type 2 Diabetic Patients With Repeated Doses of E1 in Combination With G1

A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

A Study Investigating the Movement of Lu AG09222 Into, Through, and Out of the Body of Healthy Caucasian, Chinese, and Japanese Participants

Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess

Dupilumab Severe Eosinophilic Chronic Sinusitis Without Nasal Polyposis

Efficacy and Safety of Subcutaneous Administration of Fremanezumab (TEV-48125) for the Preventive Treatment of Migraine

Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense

A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine

Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis

A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)

A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache

Rilonacept for Treatment of Familial Mediterranean Fever (FMF)

A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma

A Study of LAD603 in Adults With Alopecia Areata

Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia

Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIIB107 in Healthy Adult Participants